Oppenheimer & Co’s Rigel Pharmaceuticals RIGL Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2022
Q3 | – | Sell |
-4,259
| Closed | -$48K | – | 1448 |
|
|
2022
Q2 | $48K | Sell |
4,259
-1,065
| -20% | -$21.4K | ﹤0.01% | 1366 |
|
|
2022
Q1 | $159K | Sell |
5,324
-356
| -6% | -$9.64K | ﹤0.01% | 1385 |
|
|
2021
Q4 | $151K | Sell |
5,680
-459
| -7% | -$13.8K | ﹤0.01% | 1426 |
|
|
2021
Q3 | $223K | Sell |
6,139
-20,057
| -77% | -$789K | ﹤0.01% | 1354 |
|
|
2021
Q2 | $1.14M | Buy |
26,196
+19,774
| +308% | +$747K | 0.02% | 698 |
|
|
2021
Q1 | $220K | Sell |
6,422
-114
| -2% | -$4.51K | ﹤0.01% | 1313 |
|
|
2020
Q4 | $229K | Sell |
6,536
-11
| -0.2% | -$318 | ﹤0.01% | 1195 |
|
|
2020
Q3 | $157K | Sell |
6,547
-115
| -2% | -$2.82K | ﹤0.01% | 1192 |
|
|
2020
Q2 | $122K | Buy |
6,662
+100
| +2% | +$1.8K | ﹤0.01% | 1190 |
|
|
2020
Q1 | $102K | Sell |
6,562
-70
| -1% | -$1.49K | ﹤0.01% | 1117 |
|
|
2019
Q4 | $142K | Sell |
6,632
-174
| -3% | -$3.58K | ﹤0.01% | 1220 |
|
|
2019
Q3 | $127K | Sell |
6,806
-464
| -6% | -$9.59K | ﹤0.01% | 1201 |
|
|
2019
Q2 | $190K | Sell |
7,270
-205
| -3% | -$4.63K | 0.01% | 1197 |
|
|
2019
Q1 | $192K | Sell |
7,475
-230
| -3% | -$5.26K | 0.01% | 1232 |
|
|
2018
Q4 | $177K | Hold |
7,705
| – | – | 0.01% | 1123 |
|
|
2018
Q3 | $247K | Buy |
7,705
+275
| +4% | +$8.26K | 0.01% | 1143 |
|
|
2018
Q2 | $210K | Sell |
7,430
-384
| -5% | -$13.7K | 0.01% | 1204 |
|
|
2018
Q1 | $277K | Sell |
7,814
-207
| -3% | -$8.29K | 0.01% | 1100 |
|
|
2017
Q4 | $311K | Sell |
8,021
-2
| -0% | -$76 | 0.01% | 1038 |
|
|
2017
Q3 | $204K | Sell |
8,023
-201
| -2% | -$4.89K | 0.01% | 1183 |
|
|
2017
Q2 | $225K | Sell |
8,224
-6
| -0.1% | -$164 | 0.01% | 1129 |
|
|
2017
Q1 | $272K | Sell |
8,230
-46
| -0.6% | -$1.17K | 0.01% | 1031 |
|
|
2016
Q4 | $197K | Sell |
8,276
-33
| -0.4% | -$945 | 0.01% | 1163 |
|
|
2016
Q3 | $305K | Sell |
8,309
-367
| -4% | -$10.5K | 0.01% | 979 |
|
|
2016
Q2 | $193K | Sell |
8,676
-601
| -6% | -$14.9K | 0.01% | 1104 |
|
|
2016
Q1 | $193K | Buy |
9,277
+42
| +0.5% | +$1.04K | 0.01% | 1105 |
|
|
2015
Q4 | $280K | Sell |
9,235
-438
| -5% | -$13.3K | 0.01% | 981 |
|
|
2015
Q3 | $239K | Sell |
9,673
-8
| -0.1% | -$239 | 0.01% | 1085 |
|
|
2015
Q2 | $311K | Buy |
9,681
+289
| +3% | +$11K | 0.01% | 1079 |
|
|
2015
Q1 | $335K | Buy |
+9,392
| New | +$258K | 0.01% | 1058 |
|
|
2013
Q4 | – | Sell |
-2,000
| Closed | -$72K | – | 1447 |
|
|
2013
Q3 | $72K | Sell |
2,000
-70
| -3% | -$2.56K | ﹤0.01% | 1265 |
|
|
2013
Q2 | $69K | Buy |
+2,070
| New | +$93.8K | ﹤0.01% | 1224 |
|
Other funds holding RIGL
AC
Oppenheimer & Co's RIGL Position: Q3 2022 in Review
Oppenheimer & Co sold out of Rigel Pharmaceuticals (RIGL) in Q3 2022, closing a stake of 4,259 shares — an estimated $48K sold.
Oppenheimer & Co first reported a position in RIGL in Q2 2013 and held it in 32 quarters. The position peaked at $1.14M in Q2 2021. 138 funds tracked by Wall St. Rank hold RIGL as of Q3 2022.
- Oppenheimer & Co reported no remaining Rigel Pharmaceuticals position as of Q3 2022 after selling out during the quarter.
- Oppenheimer & Co sold 4,259 Rigel Pharmaceuticals shares in Q3 2022, an estimated $48K.
- Oppenheimer & Co first reported a position in Rigel Pharmaceuticals in Q2 2013 and held it in 32 quarters.
- Oppenheimer & Co's Rigel Pharmaceuticals position peaked at $1.14M in Q2 2021.
- 138 funds tracked by Wall St. Rank held Rigel Pharmaceuticals as of Q3 2022.
Based on Oppenheimer & Co's 13F filing for Q3 2022, filed 14 Nov 2022.